{
    "symbol": "CLVS",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-04 12:30:34",
    "content": " Of course, the highlight for the first quarter was the release of top-line results from ATHENA-MONO, the monotherapy portion of our Phase 3 ATHENA study of Rubraca as first line maintenance treatment for ovarian cancer results of which exceeded our expectations. Data from ATHENA-combo, the combination of Rubraca plus Opdivo versus Rubraca monotherapy, are expected in the first quarter of 2023, as previously announced, The only opportunity for monotherapy Rubraca in frontline ovarian cancer, the ATHENA combo study represents the potential to introduce an anti-PD-1 containing regimen for the first time to a broad population of ovarian cancer patients."
}